With the help of lead investor BB Biotech Ventures, BioVascular rounded up $10.87 million in series C financing. The San Diego, CA-based company plans on using the money to complete clinical trials of its two compounds, Saratin and BVI-007. Saratin--which is currently in Phase I/II--is being developed to reduce the failure of vascular grafts due to intimal hyperplasia. BVI-007 reduces platelet production without affecting platelet function, and is being studied in a Phase Ib dose selection clinical trial.
- see BioVascular's release for more